Literature DB >> 3931928

A microtitre cytotoxicity assay useful for the discovery of fermentation-derived antitumor agents.

J J Catino, D M Francher, K J Edinger, D A Stringfellow.   

Abstract

A microtiter cytoxicity assay using mammalian cell lines was developed to detect fermentation-derived antitumor agents. Two murine (AKR, B16) and four human (HTB-31, KB, MOSER, RCA) cell lines were used to evaluate 2000 fermentation broth supernatants. The mammalian cell lines tested showed different spectra for fermentation broth activity, as predicted by responses to known antitumor agents. Data were compared with standard antimicrobial assays historically used to screen for antitumor activity for this set of 2000 broths. There was an overlap of approximately 30% of broths identified as containing in vitro bioactivity by the two assay systems. Sixty-three antimicrobially active broths were tested for activity in P388 in vivo; the cytotoxicity assay predictive rate (40%) was twice that of the antimicrobial assays.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3931928     DOI: 10.1007/bf00263894

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  A comparative study of the use of microorganisms in the screening of potential antitumor agents.

Authors:  G E FOLEY; R E McCARTHY; V M BINNS; E E SNELL; B M GUIRARD; G W KIDDER; V C DEWEY; P S THAYER
Journal:  Ann N Y Acad Sci       Date:  1958-12-05       Impact factor: 5.691

2.  In vitro growth inhibition by 3837 compounds tested for antitumor activity: comparison of tumor cell culture and microbial assays.

Authors:  P S Thayer; H L Gordon; M Macdonald
Journal:  Cancer Chemother Rep 2       Date:  1971-04

3.  Cytotoxicity assays with L1210 cells in vitro: comparison with L1210 in vivo and KB cells in vitro.

Authors:  P S Thayer; P Himmelfarb; G L Watts
Journal:  Cancer Chemother Rep 2       Date:  1971-04

4.  A multi-end point in vitro system for detection of new antitumor drugs.

Authors:  L J Hanka; B K Bhuyan; D G Martin; G L Neil; J D Douros
Journal:  Antibiot Chemother (1971)       Date:  1978

5.  Fingerprint methods used to identify known antineoplastic agents in culture filtrates.

Authors:  R H Bunge; D E McCready; L A Balta; B D Graham; J C French; H W Dion
Journal:  Recent Results Cancer Res       Date:  1978

6.  In vitro methods used in detection and quantitation of antitumor drugs produced by microbial fermentations.

Authors:  L J Hanka; D G Martin; G L Neil
Journal:  Lloydia       Date:  1978 Mar-Apr

Review 7.  Key enzymes and tumor cell heterogeneity.

Authors:  G Weber
Journal:  Antibiot Chemother (1971)       Date:  1980
  7 in total
  6 in total

1.  Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30.

Authors:  W C Rose; G A Basler; P A Trail; M Saulnier; A R Crosswell; A M Casazza
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

2.  Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agent.

Authors:  J E Schurig; W C Rose; H Kamei; Y Nishiyama; W T Bradner; D A Stringfellow
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

3.  The PIT method: an automated in vitro technique for drug toxicity testing.

Authors:  R van Lambalgen; P Lelieveld
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Esperamicins, a class of potent antitumor antibiotics: mechanism of action.

Authors:  B H Long; J Golik; S Forenza; B Ward; R Rehfuss; J C Dabrowiak; J J Catino; S T Musial; K W Brookshire; T W Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

5.  Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo.

Authors:  J J Catino; D M Francher; J E Schurig
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Experimental antitumor activity of BMY-28090, a new antitumor antibiotic.

Authors:  J E Schurig; W T Bradner; G A Basler; W C Rose
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.